Table 3.
Comparison of Characteristics at 2 Years after ETV Commencement between LC Patients with and without HCC Development
| Characteristics | Non-HCC (n=279) | HCC (n=80) | p-value |
|---|---|---|---|
| Age, yr | 52±9 | 57±8 | <0.001 |
| Male sex | 176 (63.1) | 55 (68.8) | 0.031 |
| AST, IU/L | 33±14 | 40±13 | 0.019 |
| ALT, IU/L | 31±18 | 31±13 | 0.929 |
| Albumin, g/dL | 4.1±0.5 | 4.0±0.5 | 0.011 |
| Total bilirubin, mg/dL | 1.2±0.7 | 1.4±1.5 | 0.333 |
| INR | 1.14±0.64 | 1.14±0.22 | 0.994 |
| Platelet count, ×103/μL | 110±44 | 96±42 | 0.018 |
| HBeAg positivity | 98 (37.0) | 29 (40.3) | 0.681 |
| Partial virological response | 21 (7.5) | 14 (17.5) | 0.023 |
| CP class | 0.882 | ||
| A | 251 (90.0) | 71 (88.8) | |
| B | 26 (9.3) | 8 (10.0) | |
| C | 2 (0.7) | 1 (1.2) | |
| MELD | 6.3±4.5 | 6.0±3.2 | 0.612 |
| APRI | 1.5±1.6 | 1.5±1.1 | 0.954 |
| FIB-4 index | 3.5±2.3 | 5.1±3.6 | <0.001 |
Data are presented as mean±SD or number (%).
ETV, entecavir; LC, liver cirrhosis; HCC, hepatocellular carcinoma; AST, aspartate aminotransferase; ALT, alanine aminotransferase; INR, international normalized ratio; HBeAg, hepatitis B e antigen; CP, Child-Pugh; MELD, Model for End-Stage Liver Disease; APRI, aspartate transaminase to platelet ratio index.